Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Developer of drugs for reproductive system conditions reports Q2 2005 results
September 15th, 2005
Zonagen, Inc. (ZONA) reported financial results for the 3-month and 6-month periods ended June 30, 2005 and provided an update on its clinical development efforts for Proellex (formerly called Progenta) and Androxal, and the patent proceeding related to its Androxal product candidate. "We continue to make progress toward our goal of initiating three clinical trials by year end 2005 which include a U.S. phase 3 trial of Androxal for male testosterone deficiency, a U.S. efficacy trial of Proellex for uterine fibroids and a European phase 2 trial of Proellex for endometriosis," said Joseph Podolski, president and CEO of Zonagen, Inc. "We anticipate initial study data from...
Source: Women's Health Weekly (2005-09-15)
|
